Behavioral Exercise Training to Reduce Cardiovascular Disease Risk (EXTRA-PC)

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk in Men Undergoing Androgen Deprivation Therapy (EXTRA-PC)

To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak & 6-minute walk distance [6MWD]) among prostate cancer (PC) patients compared to controls receiving healthy living education (HLE) at 12 weeks.

Study Overview

• Status: Recruiting
• Conditions: Prostate Cancer; Supportive Care
• Intervention / Treatment: Behavioral: Exercise Training Intervention; Behavioral: Healthy Living Education

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Alexander R Lucas, PhD; Phone Number: 804 628-6610; Email: Alexander.Lucas@vcuhealth.org
• Study Contact Backup: Name: Alexandra Marshall, MS; Phone Number: 804 628-1215; Email: lara.marshall@vcuhealth.org

Study Locations

• United States
  • Virginia
    • Richmond, Virginia, United States, 23298
      • Recruiting
      • Virginia Commonwealth University Massey Cancer Center
      • Contact: Alexandra Marshall; Email: marshallla@vcu.edu
      • Contact: Alexander Lucas, PhD; Phone Number: 804-628-6610; Email: Alexander.Lucas@vcuhealth.org
      • Principal Investigator: Alexander Lucas, Ph.D
    • Richmond, Virginia, United States, 23249
      • Not yet recruiting
      • Richmond Veterans Affairs Medical Center
      • Contact: Alexander R Lucas, PhD; Phone Number: 804-628-6610; Email: Alexander.Lucas2@va.gov
      • Contact: Alexandra L Marshall, MS; Phone Number: 804 628-1215; Email: lara.marshall@vcuhealth.org
      • Principal Investigator: Alexander R Lucas, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Be diagnosed with stage II/III/IV prostate cancer
• Be currently undergoing treatment with ADT (intermittent or prolonged)
• Have completed local curative-intent treatment, including prostatectomy or definitive radiation;
• Be >40 years of age up to 85;
• Be willing to sign an informed consent with HIPAA authorization form;
• Not have any hearing or sight impairments that result in the inability to use the telephone or hear normal conversation;
• Must be able to join an intervention group by personal computer, smartphone or telephone call and should agree to recording of an interview;
• Be without any serious medical condition that precludes safe participation in an exercise program;
• Speak English

Exclusion Criteria:

• Be unable to undergo MRI (i.e., ferromagnetic materials in body, inability to lie flat, claustrophobia);
• Have contraindications to exercise testing;
• Have pre-existing overt cardiovascular disease/heart failure;
• Active illness/infection;
• Hemoglobin < 7.0 grams/dL
• Platelet count < 10 x 109/L

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Exercise Training Intervention; The exercise program (ET) is tailored to each participant depending on his initial functional capacity, cardiorespiratory fitness and strength, to achieve ≥150 moderate to vigorous physical activity	Behavioral: Exercise Training Intervention; 5.1. The behavioral ET and HLE interventions will be delivered over 12 weeks. Before starting the study, men will be asked to attend one (1) in-person small group orientation to provide an overview of each intervention arm, familiarize them with web-based and smartphone applications or hard copy manuals for delivery of intervention content, exercise logs, resistance bands, and equipment for strength training.; Other Names: Behavioral, Exercise Training
Active Comparator: Healthy Living Education Control; Educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.	Behavioral: Healthy Living Education; During the initial 12 weeks of the study, men randomized to the HLE group will receive educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in maximal exercise capacity (VO2 peak) at 12 weeks	Exercise capacity will be measured by the maximal volume of oxygen utilization (VO2 peak) during a supine graded cardiopulmonary exercise test done in conjunction with cardiac magnetic resonance (exeCMR+CPET). VO2 will be measured in both relative (ml/kg/minute) and absolute (L/minute) terms.	Baseline, 12 weeks, and 24 weeks
Change from baseline in sub-maximal exercise capacity (6MWD) at 12 weeks	The distance walked in a sub-maximal 6-minute walk test (6MWD). 6MWD will be reported as meters walked (m).	Baseline, 12 weeks, and 24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stroke Volume (SV) as a cardiac determinant of exercise capacity among men undergoing ADT following 12 weeks of ET vs HLE controls.	By measuring resting and exercise -associated left ventricular (LV) end-diastolic (EDV) and end-systolic volumes (ESV) we will calculate stroke volume (SV) in milliliters/beat (ml). SV = EDV - ESV	Baseline, 12 weeks
Left ventricular ejection fraction (LVEF) as a cardiac determinant of exercise capacity among men undergoing ADT following 12 weeks of ET vs HLE controls.	By measuring resting and exercise-associated stroke volumes (SV) as a proportion of end-diastolic volumes (EDV) we will calculate left ventricular ejection fraction (%). LVEF = SV/EDV	Baseline, 12 weeks
Cardiac output (CO) as a cardiac determinant of exercise capacity among men undergoing ADT following 12 weeks of ET vs HLE controls.	By measuring resting and exercise-associated stroke volume (SV) and the heart rate (HR) in conjunction with image acquisition we will calculate cardiac output in liters per minute (L/min). CO = SV x HR	Baseline, 12 weeks
Arterial-venous oxygen (a-vO2) difference as a musculoskeletal determinant of exercise capacity among men undergoing ADT following 12 weeks of ET vs HLE controls.	From the exercise tests we will calculate a-vO2 difference using the FICK equation. The difference in oxygen saturation between the venous circulation and the arterial circulation will be reported in milliliters (ml) and also expressed as ml/100ml of blood (%) a-vO2 = VO2 / CO	Baseline, 12 weeks
Change in lean body mass	We will conduct body composition assessments using bioelectrical impedance analysis (BIA) and a Dual Energy X-Ray Absorptiometry (DXA) scan. We will use dual X-ray absorptiometry (DEXA) to assess whole body composition for lean body mass. Lean body mass will be reported as kilograms (kg)	Baseline, 12 weeks
Change in fat mass	We will conduct body composition assessments using bioelectrical impedance analysis (BIA) and a Dual Energy X-Ray Absorptiometry (DXA) scan. We will use dual X-ray absorptiometry (DEXA) to assess whole body composition for fat mass as well as distribution patterns of adiposity, e.g., visceral adipose tissue. Fat mass and visceral fat mass will be reported in kilograms (kg) and body fat percentage will be reported as fat mass / body mass (%)	Baseline, 12 weeks
Neighborhood Environment & Walkability Survey (NEWS-A)	NEWS-A is a validated self-reported survey used to assess factors that are correlates or determinants of participants ability to engage in physical activity in their neighborhoods. For example, higher walkability is determined by availability of sidewalks and access to nearby facilities.	Baseline, 12 weeks, 24 weeks
Change in physical activity assessed with the Godin Leisure-Time Exercise Questionnaire (GLTEQ)	GLTEQ is a self-report survey to determine the level typical activity a participant engages in each week. Higher scores on the index indicate more activity.	Baseline, 12 weeks, 24 weeks
Change in physical activity assessed with Accelerometry	The ActivPAL and Actigraph accelerometers provide an objective assessment of sedentary sitting time and increasing intensities of physical activity in minutes per week	Baseline, 12 weeks, 24 weeks
Change in self-efficacy to navigate barriers to engaging in exercise	A self report of self-efficacy to engage in exercise or physical activity under different challenging conditions such as when experiencing fatigue. Higher scores indicate increased confidence to navigate barriers.	Baseline, 12 weeks, 24 weeks
Change in self-efficacy to walk for increasing periods of time.	A self report of self-efficacy to engage in walking for an increasing period of time. Higher scores indicate increased confidence to walk for a longer periods of time without resting.	Baseline, 12 weeks, 24 weeks
Change in Functional Assessment of Cancer Therapy - Prostate (FACT-P) scores	FACT-P is a validated self report measures of different domains of quality of life that are important for men who have been diagnosed with prostate cancer. Subscale scores can be assessed to gauge functional wellbeing, physical wellbeing, social wellbeing and emotional wellbeing as well as prostate specific wellbeing. Higher scores indicate a higher quality of life on overall and sub scales.	Baseline, 12 weeks, 24 weeks
Change in health-related quality of life (SF-36) scores	SF-36 (RAND) is a validated self report measure of different domains of health-related quality of life that are important for adults. Higher scores indicate a higher health-related quality of life .	Baseline, 12 weeks, 24 weeks
Change in fatigue measured with the patient reported outcomes measurement information system (PROMIS) - Fatigue scores	PROMIS - Fatigue is a validated self-report measure of fatigue among patients diagnosed with cancer and higher scores indicate a lower level of fatigue.	Baseline, 12 weeks, 24 weeks
Change in physical function measured with the patient reported outcomes measurement information system (PROMIS) - Physical Functioning scores	PROMIS - Physical Functioning is a validated self-report measure of physical functioning among patients diagnosed with cancer and higher scores indicate a better function.	Baseline, 12 weeks, 24 weeks
Change in sleep disturbance measured with the patient reported outcomes measurement information system (PROMIS) - Sleep Disturbance scores	PROMIS - Sleep Disturbance is a validated self-report measure of sleep disturbance among patients diagnosed with cancer and higher scores indicate less sleep disruption.	Baseline, 12 weeks, 24 weeks
Change in depressive symptoms measured with the patient reported outcomes measurement information system (PROMIS) - Depression scores	PROMIS - Depression is a validated self-report measure of depressive symptoms among patients diagnosed with cancer and higher scores indicate less symptoms.	Baseline, 12 weeks, 24 weeks
Change in anxiety measured with the patient reported outcomes measurement information system (PROMIS) - Anxiety scores	PROMIS - Anxiety is a validated self-report measure of depressive symptoms among patients diagnosed with cancer and higher scores indicate less symptoms.	Baseline, 12 weeks, 24 weeks
Change in emotional distress measured with the patient reported outcomes measurement information system (PROMIS) - Emotional Distress scores	PROMIS - Anxiety is a validated self-report measure of depressive symptoms among patients diagnosed with cancer and higher scores indicate less symptoms.	Baseline, 12 weeks, 24 weeks
Change in fatigue measured with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scale	FACUT-F is a validated self-report measure of fatigue among patients undergoing treatment for a chronic illness and higher scores indicate less fatigue.	Baseline, 12 weeks, 24 weeks
Change in perceived stress as measured with Cohen's perceived stress scale (PSS)	PSS is a validated self-report measure of perceived stress and higher scores indicate more perceived stress.	Baseline, 12 weeks, 24 weeks
Change in physical function assessed with the Short Physical Performance Battery (SPPB)	SPPB is a validated objective assessment of 3 domains of physical function that includes gait speed, grip strength and time taken to stand from a chair 5 times. Each down is scored on a scale of 0-4 with a total score summed from each domain. A higher score is indicative of better functioning.	Baseline, 12 weeks, 24 weeks

Collaborators and Investigators

• Sponsor: Virginia Commonwealth University
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
• Investigators: Principal Investigator: Alexander R Lucas, PhD, Virginia Commonwealth University

Study record dates

Study Major Dates

• Study Start (Actual): February 21, 2024
• Primary Completion (Estimated): January 31, 2028
• Study Completion (Estimated): January 31, 2028

Study Registration Dates

• First Submitted: January 4, 2024
• First Submitted That Met QC Criteria: January 31, 2024
• First Posted (Actual): February 1, 2024

Study Record Updates

• Last Update Posted (Actual): March 2, 2026
• Last Update Submitted That Met QC Criteria: February 26, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Exercise; Prostate Cancer; Supportive Care
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Behavior; Prostatic Neoplasms; Motor Activity; Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena; Exercise
• Other Study ID Numbers: MCC-23-20934; HM20028583 (Other Identifier: Virginia Commonwealth University); 1K01HL161419-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No